What is the best medication for treating insomnia in an adult with multiple sclerosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Best Medication for Insomnia in Multiple Sclerosis

For adults with MS and insomnia, use eszopiclone (2-3 mg) or zolpidem (10 mg) as first-line pharmacologic options, with the critical caveat that cognitive behavioral therapy for insomnia (CBT-I) should be prioritized first given the unique safety concerns in this population.

Recommended Pharmacologic Approach

First-Line Medications

Based on the 2017 American Academy of Sleep Medicine guidelines 1, the following medications have evidence supporting their use in adults with chronic insomnia:

For both sleep onset AND sleep maintenance insomnia:

  • Eszopiclone 2-3 mg - This has specific evidence in the MS population 2 showing it increased total sleep time, though the study found it did not sufficiently improve MS-related fatigue
  • Zolpidem 10 mg - Effective for both sleep onset and maintenance
  • Temazepam 15 mg - Benzodiazepine option, though carries higher risk profile

For sleep onset insomnia only:

  • Zaleplon 10 mg
  • Triazolam 0.25 mg
  • Ramelteon 8 mg (melatonin agonist)

For sleep maintenance insomnia only:

  • Suvorexant 10-20 mg (orexin receptor antagonist)
  • Doxepin 3-6 mg (low-dose tricyclic)

Critical Safety Considerations in MS Patients

The 2016 American College of Physicians evidence report 3 identified serious concerns with hypnotics that are particularly relevant to MS patients:

  • Increased risk of dementia, fractures, and major injury from observational studies
  • Cognitive and behavioral changes including driving impairment
  • Dose reduction recommended in older adults and women

These risks are amplified in MS patients who already face mobility challenges, cognitive dysfunction, and fall risk. The absolute effect sizes for all pharmacologic treatments were small 3.

MS-Specific Evidence

The only MS-specific pharmacologic trial 2 tested eszopiclone versus placebo in 30 patients with relapsing-remitting MS. While eszopiclone increased total sleep time compared to placebo, it did not improve the multifactorial nature of sleep disturbances or fatigue in MS patients. This suggests that medication alone is insufficient for managing insomnia in MS.

Strongly Recommended Non-Pharmacologic First-Line Approach

Cognitive behavioral therapy for insomnia (CBT-I) should be the initial treatment before considering medications 4, 5. A 2022 pilot study 5 demonstrated that telehealth-delivered CBT-I in MS patients achieved:

  • 100% retention and adherence
  • Significant improvements in insomnia severity, sleep quality, fatigue, depression, and quality of life
  • Outcomes equivalent to in-person CBT-I
  • Accessibility for patients across multiple states, addressing mobility and geographic barriers

This is particularly important given that insomnia affects 52% of MS patients by symptoms and 22% by diagnostic criteria 6, with women disproportionately affected.

Medications to AVOID

The AASM guidelines explicitly recommend against the following 1:

  • Trazodone 50 mg - Insufficient evidence
  • Tiagabine - Not recommended despite being an anticonvulsant
  • Diphenhydramine - Anticholinergic burden problematic in MS
  • Melatonin 2 mg - Insufficient evidence
  • Valerian, L-tryptophan - No evidence of benefit

Clinical Algorithm

  1. First: Refer for telehealth or in-person CBT-I (6 weekly sessions) 5
  2. If CBT-I insufficient or unavailable: Consider pharmacotherapy
  3. Characterize insomnia type:
    • Sleep onset + maintenance → Eszopiclone 2-3 mg (has MS-specific data) or Zolpidem 10 mg
    • Sleep onset only → Zaleplon 10 mg or Ramelteon 8 mg (safer profile)
    • Sleep maintenance only → Doxepin 3-6 mg (lower cognitive risk than benzodiazepines)
  4. Reassess in 4 weeks - All guideline evidence is based on short-term trials; long-term efficacy unknown 3
  5. Monitor closely for cognitive changes, falls, and driving impairment

Important Caveats

  • All pharmacologic recommendations carry WEAK strength ratings in the guidelines 1, reflecting low-to-moderate quality evidence
  • First-line disease-modifying therapies (especially interferon-beta) may worsen sleep, while second-line treatments (natalizumab) may improve it 7
  • The multifactorial nature of sleep disturbances in MS (pain, spasticity, nocturia, mood disorders) means addressing underlying contributors is essential 2
  • Women with MS have higher insomnia prevalence and should be prioritized for intervention 6

References

1
Guideline

clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an american academy of sleep medicine clinical practice guideline.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2017

Related Questions

What are the recommended sleep medications and management strategies for a patient with multiple sclerosis?
Are sleeping medicines safe for patients with multiple sclerosis (MS) experiencing exacerbations?
What are the recommended prazosin dosing regimens for adults with hypertension and PTSD-related nightmares, including adjustments for elderly patients or those with renal or hepatic impairment?
Is a serum sodium of 142 mmol/L normal and does it indicate any abnormal water balance or electrolyte disturbance in an asymptomatic adult with a random nighttime urine osmolality of 267 mOsm/kg?
What is the normal range for heart rate variability (HRV) in a 64‑year‑old female?
Can phenol 1.4% lozenges be used for sore throat relief in healthy adults, and what are the recommended dosing and contraindications?
What patient education should be provided for rhabdomyolysis regarding hydration, activity restrictions, medication management, symptom monitoring, and when to seek medical care?
What is the minimum prescribed dose of gabapentin?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.